Can allergy drugs help kids tolerate peanut and more?
NCT ID NCT03679676
First seen Jun 08, 2026 · Last updated Jun 21, 2026 · Updated 2 times
Summary
This study tested whether adding the drugs omalizumab (Xolair) or dupilumab (Dupixent) to oral immunotherapy (OIT) helps people with multiple food allergies tolerate more allergens. 130 participants aged 4 to 55 with allergies to peanut plus one or two other foods were enrolled. The goal was to see if these biologics improve the success of passing a food challenge to peanut and other allergens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERSENSITIVITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sean N. Parker Center for Allergy & Asthma Research at Stanford University
Palo Alto, California, 94304, United States
-
University of California Los Angeles (UCLA)
Los Angeles, California, 90095, United States
-
University of California San Diego (UCSD)
San Diego, California, 92123, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omalizumab (Xolair) and dupilumab (Dupixent)
What this could lead to
If successful, this could lead to a safer and more effective way to treat multiple food allergies at once, reducing the risk of severe allergic reactions.
What could go wrong
This is a Phase 2 trial with a moderate number of participants, so results may not apply to everyone. The biologics can have side effects, and the treatment may not work for all allergens.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.